Quest Diagnostics (DGX) 44th Annual J.P. Morgan Healthcare Conference summary

Business overview and market position

• Serves one-third of the U.S. adult population annually, with 220 million requisitions and 80 million direct blood draws in 2024.

• Operates over 8,000 blood draw locations and manages 80 billion patient data points from the past decade.

• Holds a 12% share in the physician office lab market and runs a growing $800 million hospital co-lab business, expected to reach $1 billion by 2026.

• Recent Canadian acquisition expanded reach to 25% of the Canadian population, mainly in Ontario and British Columbia.

• B2B focus remains strong, with 4%-5% organic growth guidance and expansion into new geographies and large health systems.

Growth drivers and innovation

• Consumer-initiated testing grew from $30 million in 2021 to $250 million in 2024, with direct channels and partners like Function Health and wearables companies.

• Advanced diagnostics in cardiometabolic health, autoimmune disorders, and brain health, including proprietary Alzheimer's blood tests.

• AI and automation deployed in labs and customer service, improving productivity and enabling digital cytology and dynamic route optimization.

• M&A remains a key strategy, with $2.8 billion deployed over three years, focusing on regional labs, health system outreach, and capability building.

• Operating margin targeted to improve by 75-150 basis points, with continued focus on cost productivity and patient experience.

Industry trends and strategic outlook

• Demographic shifts toward an older, sicker population drive demand for chronic disease and wellness testing.

• Prevention and wellness currently make up one-third of revenue, with ambitions to increase this share.

• Partnerships with large physician groups and health systems enable scale and IT integration, supporting national reach.

• AI tools for both patients and physicians aim to enhance result interpretation and trend analysis.

• Guidance reaffirmed for 4%-5% revenue growth, 7%-9% adjusted EPS growth, and $3-$3.3 billion free cash flow from 2025-2027.